Cargando…

Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome

INTRODUCTION: Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune disease which has focal lymphocytic infiltration including a majority of CD4+ T cells. This study was to investigate the correlation of peripheral granzyme B (GranzB)-expressing CD4+ T cells with disease severity and his...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qi, Che, Nan, Lu, Chengyin, Sun, Xiaoxuan, Wang, Yanyan, Wang, Qiang, Tan, Wenfeng, Zhou, Lanlan, Zhang, Xiaojun, Xu, Dong, Gu, Lei, Zhang, Miaojia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507116/
https://www.ncbi.nlm.nih.gov/pubmed/34641948
http://dx.doi.org/10.1186/s13075-021-02632-6
_version_ 1784581788720431104
author Wang, Qi
Che, Nan
Lu, Chengyin
Sun, Xiaoxuan
Wang, Yanyan
Wang, Qiang
Tan, Wenfeng
Zhou, Lanlan
Zhang, Xiaojun
Xu, Dong
Gu, Lei
Zhang, Miaojia
author_facet Wang, Qi
Che, Nan
Lu, Chengyin
Sun, Xiaoxuan
Wang, Yanyan
Wang, Qiang
Tan, Wenfeng
Zhou, Lanlan
Zhang, Xiaojun
Xu, Dong
Gu, Lei
Zhang, Miaojia
author_sort Wang, Qi
collection PubMed
description INTRODUCTION: Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune disease which has focal lymphocytic infiltration including a majority of CD4+ T cells. This study was to investigate the correlation of peripheral granzyme B (GranzB)-expressing CD4+ T cells with disease severity and histological lesion in patients with pSS. METHODS: We recruited 116 pSS and 46 health control (HC) using flow cytometry to examine the percentage of CD4+GranzB+CTLs in the peripheral blood, and immunofluorescence to test their expression in the labial gland. RESULTS: The percentage of CD4+GranzB+CTLs was significantly upregulated in pSS than in HC (7.1 ± 4.9% vs 3.1 ± 1.9%, p < 0.0001) and positive correlation with ESSDAI. The frequency of them was markedly higher in pSS with extraglandular manifestations. After excluding the other risk factors associated with pSS, they were still related to ESSDIA and extraglandular manifestations independently (p < 0.05), and they are the risk factor of extraglandular involvement (odds ratio = 1.928). Moreover, they could be observed in the LSGs. ROC curve analysis indicated that the area under the curve (AUC) of CD4+GranzB+CTLs was 0.796 to predict the activity of pSS and 0.851 to presume extraglandular manifestations. The best diagnostic cutoff point was 4.865 for pSS patients. CONCLUSION: In this study, we provide new evidence indicating the involvement of CD4+GranzB+CTLs over activation in the pathophysiology of pSS, which may serve as a new biomarker to evaluate the activity and severity of pSS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02632-6.
format Online
Article
Text
id pubmed-8507116
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85071162021-10-25 Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome Wang, Qi Che, Nan Lu, Chengyin Sun, Xiaoxuan Wang, Yanyan Wang, Qiang Tan, Wenfeng Zhou, Lanlan Zhang, Xiaojun Xu, Dong Gu, Lei Zhang, Miaojia Arthritis Res Ther Research Article INTRODUCTION: Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune disease which has focal lymphocytic infiltration including a majority of CD4+ T cells. This study was to investigate the correlation of peripheral granzyme B (GranzB)-expressing CD4+ T cells with disease severity and histological lesion in patients with pSS. METHODS: We recruited 116 pSS and 46 health control (HC) using flow cytometry to examine the percentage of CD4+GranzB+CTLs in the peripheral blood, and immunofluorescence to test their expression in the labial gland. RESULTS: The percentage of CD4+GranzB+CTLs was significantly upregulated in pSS than in HC (7.1 ± 4.9% vs 3.1 ± 1.9%, p < 0.0001) and positive correlation with ESSDAI. The frequency of them was markedly higher in pSS with extraglandular manifestations. After excluding the other risk factors associated with pSS, they were still related to ESSDIA and extraglandular manifestations independently (p < 0.05), and they are the risk factor of extraglandular involvement (odds ratio = 1.928). Moreover, they could be observed in the LSGs. ROC curve analysis indicated that the area under the curve (AUC) of CD4+GranzB+CTLs was 0.796 to predict the activity of pSS and 0.851 to presume extraglandular manifestations. The best diagnostic cutoff point was 4.865 for pSS patients. CONCLUSION: In this study, we provide new evidence indicating the involvement of CD4+GranzB+CTLs over activation in the pathophysiology of pSS, which may serve as a new biomarker to evaluate the activity and severity of pSS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02632-6. BioMed Central 2021-10-12 2021 /pmc/articles/PMC8507116/ /pubmed/34641948 http://dx.doi.org/10.1186/s13075-021-02632-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wang, Qi
Che, Nan
Lu, Chengyin
Sun, Xiaoxuan
Wang, Yanyan
Wang, Qiang
Tan, Wenfeng
Zhou, Lanlan
Zhang, Xiaojun
Xu, Dong
Gu, Lei
Zhang, Miaojia
Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome
title Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome
title_full Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome
title_fullStr Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome
title_full_unstemmed Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome
title_short Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjögren’s syndrome
title_sort correlation of peripheral cd4+granzb+ctls with disease severity in patients with primary sjögren’s syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507116/
https://www.ncbi.nlm.nih.gov/pubmed/34641948
http://dx.doi.org/10.1186/s13075-021-02632-6
work_keys_str_mv AT wangqi correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT chenan correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT luchengyin correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT sunxiaoxuan correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT wangyanyan correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT wangqiang correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT tanwenfeng correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT zhoulanlan correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT zhangxiaojun correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT xudong correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT gulei correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome
AT zhangmiaojia correlationofperipheralcd4granzbctlswithdiseaseseverityinpatientswithprimarysjogrenssyndrome